UM spinoff Lycera starts anti-cancer drug trials

UM spinoff Lycera starts anti-cancer drug trials

Lycera Corp., a University of Michigan spinoff developing drugs that target cancer and diseases of the immune system, has started human trials that could lead to the sale of the company next year. In December, the company finished a phase 1 U.S. Food

(Visited 1 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.